Phase II Clinical Trial of TROGLITAZONE, a Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Antineoplastic Differentiation Therapy for Patients With Malignant Liposarcoma

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically proven liposarcoma that is incurable by standard
surgery Measurable or evaluable disease required No active CNS involvement or
leptomeningeal disease

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At
least 12 weeks Hematopoietic: Absolute neutrophil count at least 1500/mm3 Platelet count
at least 100,000/mm3 Hepatic: Bilirubin no greater than 2.0 mg/dL SGOT less than 5 times
upper normal limit Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: No poorly
controlled atrial arrhythmias, angina pectoris, or myocardial infarction within past 6
months No symptomatic congestive heart failure, percutaneous transluminal coronary
angioplasty, or coronary artery bypass graft within past 3 months Other: Not pregnant or
nursing Fertile patients must use effective contraception No known active retroviral
disease

PRIOR CONCURRENT THERAPY: Recovered from toxic effects of all prior therapy No concurrent
cytotoxic therapy Biologic therapy: Not specified Chemotherapy: Prior chemotherapy allowed
Endocrine therapy: No concurrent hormonal therapy Radiotherapy: Prior radiation therapy
for metastatic disease allowed No radiotherapy to sole site of measurable disease within
past 6 months Surgery: Not specified